Clinical follow-up of children with immune-tolerant chronic hepatitis B receiving antiviral therapy

Pan ZHAO; Yi DONG; Jiaqi LIU; Xue GAO; Yiwei WU; Shishu ZHU; Limin WANG; Zhenman WEI

doi:10.3969/j.issn.1001-5256.2021.07.016

Volume 37 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(7): 1558-1560

PDF( 2006 KB)

Clinical follow-up of children with immune-tolerant chronic hepatitis B receiving antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.07.016

Pan ZHAO^{a
,
,},
Yi DONG^b,
Jiaqi LIU^a,
Xue GAO^c,
Yiwei WU^a,
Shishu ZHU^{d
,
,},
Limin WANG^b,
Zhenman WEI^a

a.
Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
b.
Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
c.
Department of Pathology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
d.
Department of Health Examination, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Research funding:

Beijing Municipal Science and Technology Commission (Z181100001718035);

National Natural Science Foundation of China (81501652);

Municipal Natural Science Foundation of Beijing of China (7202193)

Received Date: 2021-01-28
Accepted Date: 2021-02-23
Published Date: 2021-07-20

Abstract

Abstract

Objective To investigate the long-term clinical benefits of antiviral therapy in children with immune-tolerant chronic hepatitis B. Methods Long-term follow-up was performed for 46 children with immune-tolerant chronic hepatitis B who were enrolled in the treatment group of the previous randomized controlled trial, and clinical evaluation was performed at weeks 108, 120, 132, 144, 168, and 192 after the trial started. Results All 46 patients completed the follow-up. From week 96 (after the clinical trial started) to week 192 (when the follow-up ended), another 3 patients achieved serum HBV DNA clearance, another 7 patients achieved serum HBeAg clearance, another 6 patients achieved HBeAg seroconversion, and another 3 patients achieved HBsAg seroconversion, while there was no change in the number of patients who achieved serum HBsAg clearance, with a total number of 37 (80.4%), 22 (47.8%), 21 (45.7%), 10(21.7%), and 10(21.7%), respectively. Among these patients, 9(19.6%) did not achieve HBV DNA clearance and they all had virologic breakthrough after drug withdrawal. Conclusion Further large-sample clinical trials are needed to investigate antiviral therapy for children with immune-tolerant chronic hepatitis B.
- Hepatitis B, Chronic,
- Immune Tolerance,
- Child

FullText(HTML)

References(10)

References

[1]	CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
[2]	LIM JK, NGUYEN MH, KIM WR, et al. Prevalence of chronic hepatitis B virus infection in the United States[J]. Am J Gastroenterol, 2020, 115(9): 1429-1438. DOI: 10.14309/ajg.0000000000000651.
[3]	NASTASIO S, JONAS MM. Effect of universal infant hepatitis B virus immunization on mother-to-child hepatitis B virus transmission[J]. J Infect Dis, 2019, 220(7): 1089-1090. DOI: 10.1093/infdis/jiy707.
[4]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[5]	DELLA CORTE C, NOBILI V, COMPARCOLA D, et al. Management of chronic hepatitis B in children: An unresolved issue[J]. J Gastroenterol Hepatol, 2014, 29(5): 912-919. DOI: 10.1111/jgh.12550.
[6]	ZHU S, ZHANG H, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037.
[7]	ZHAO P, ZHONG YW, XU DP. A181 site mutation in HBV reverse transcriptase region on chronic HBV-infected patients during Entecavir therapy[J]. J Clin Hepatol, 2011, 27(3): 289-291. DOI: 10.3969/j.issn.1001-5256.2011.03.020. 赵攀, 钟彦伟, 徐东平. 5例应用恩替卡韦治疗的慢性HBV感染者发生HBV逆转录酶区单独A181位点突变的分析[J]. 临床肝胆病杂志, 2011, 27(3): 289-291. DOI: 10.3969/j.issn.1001-5256.2011.03.020.
[8]	MARTIN P. Immune-tolerant hepatitis B: Maybe a misnomer but still hard to treat[J]. Hepatology, 2019, 69(6): 2315-2317. DOI: 10.1002/hep.30654.
[9]	HSU YC, HUANG YT. Editorial: Risk assessment for chronic hepatitis B patients in the immune tolerant phase-both definition and selection matter[J]. Aliment Pharmacol Ther, 2020, 52(1): 213-214. DOI: 10.1111/apt.15798.
[10]	INDOLFI G, EASTERBROOK P, DUSHEIKO G, et al. Hepatitis B virus infection in children and adolescents[J]. Lancet Gastroenterol Hepatol, 2019, 4(6): 466-476. DOI: 10.1016/S2468-1253(19)30042-1.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (652) PDF downloads(69)

Clinical follow-up of children with immune-tolerant chronic hepatitis B receiving antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.07.016

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical follow-up of children with immune-tolerant chronic hepatitis B receiving antiviral therapy

DOI: 10.3969/j.issn.1001-5256.2021.07.016

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content